Post Operative Pain Management for ACL Reconstruction

Isolated Adductor Canal Block vs Adductor Canal Block With IPACK in ACL Reconstruction: A Randomized, Prospective Trial

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05316168

Enrollment

154

Registered

2022-04-07

Start date

2023-09-30

Completion date

2024-09-30

Last updated

2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Brief summary

Health care providers are seeking methods to limit post-operative pain and opioid prescriptions to reduce the burden of the national opioid use epidemic. Adductor canal block (ACB) is a peripheral nerve block that has been shown to reduce pain and opioid usage with minimal effect on quadriceps function in patients undergoing arthroscopic knee surgery. Infiltration between Popliteal Artery and Capsule of the Knee (iPACK) block has also shown promise in reducing pain and opioid usage, specifically reducing posterior knee pain, which ACB is not able to achieve. To our knowledge, there is currently no study in the orthopedic literature comparing post-operative pain and opioid consumption in ACL reconstruction (ACLR) patients who received isolated ACB versus ACB with IPACK. The primary aim of this study is to investigate the role of IPACK in combination with ACB in reducing peri-operative (14-days) pain levels in ACLR patients. The secondary aim is to determine the effectiveness of IPACK in reducing post-operative opioid use. The tertiary aim is to determine any effect of IPACK on post-operative functional outcomes.

Interventions

DRUGBupivacaine HCl 0.5% Injectable Solution

During adductor canal block participants will receive 20cc of Bupivacaine HCl 0.5%

DRUGDexamethasone

During adductor canal block participants will receive 2mg Dexamethasone

PROCEDUREInfiltration between Popliteal Artery and Capsule of the knee (iPACK)

Prior to closing the surgical wound participants will receive a local injections of 20cc 0.5% bupivacaine mixed with 2mg dexamethasone

DRUGPercocet 5Mg-325Mg Tablet

Participant will receive 20 Percocet 5/325mg tablets post surgery for pain control

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* All patients undergoing primary ACLR for ACL tear, including patients with concomitant meniscectomy or meniscal repair.

Exclusion criteria

* Revision ACLR, worker's compensation, pregnancy, age\<18 years

Design outcomes

Primary

Measure	Time frame	Description
Post operative pain management	14 days	This will be measured by the participants completing a pain and medication Use questionnaire
Post operative pain management 2	6 months	Participants will also complete the International Knee Documentation Committee (IKDC) questionnaires

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026